- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Familial heterozygous hypercholesterolaemia, Non-familial hypercholesterolaemia
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 877KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 57KB)
Evolocumab – November 2020
Evolocumab: Injection 140 mg in 1 mL single use pre-filled pen, Injection 420 mg in 3.5 mL single use pre-filled cartridge; Repatha®
Last updated
19 March 2021